June 3, 2015
Satoru Iwasa of National Cancer Center Hospital Three out of 20 Japanese gastric cancer patients achieved partial response (PR) to the anti-PD-L1 antibody avelumab being developed by Pfizer Inc. and Merck KGaA in a PI clinical trial. The results were...read more